HAEM5:T-prolymphocytic leukaemia: Difference between revisions
| [unchecked revision] | [checked revision] |
No edit summary |
|||
| Line 4: | Line 4: | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD | Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD | ||
Cedars-Sinai, Los Angeles, CA | |||
==WHO Classification of Disease== | ==WHO Classification of Disease== | ||
{| class="wikitable" | {| class="wikitable" | ||
| Line 207: | Line 209: | ||
**5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow | **5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow | ||
**T cell clonality by molecular or flow cytometry methods | **T cell clonality by molecular or flow cytometry methods | ||
**Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC** | **Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC** | ||
*'''Minor criteria:''' | *'''Minor criteria:''' | ||
**Abnormalities involving chromosome 11 | **Abnormalities involving chromosome 11 | ||
| Line 371: | Line 373: | ||
The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci. | The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci. | ||
* Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray) | *Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray) | ||
* PCR for TRB/TRG | *PCR for TRB/TRG | ||
* Next-Generation Sequencing (NGS) | *Next-Generation Sequencing (NGS) | ||
==Familial Forms== | ==Familial Forms== | ||